Urovant Sciences Appoints James Robinson to its Board of Directors

IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Urovant Sciences (Nasdaq: UROV), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for urologic conditions, today announced James
Robinson, President and Chief Operating Officer of Alkermes, will join
its Board of Directors.

“Jim’s extensive leadership, knowledge and experience in the
biopharmaceutical space combined with his unique understanding of the
urology market will help inform Urovant’s strategies and growth
opportunities,” said Keith A. Katkin, Chief Executive Officer of
Urovant. “Urovant is pleased to welcome him to our board and my team and
I are looking forward to his counsel and contributions.”

“Jim has demonstrated unwavering leadership in the competitive and
complex biopharmaceutical market,” said Myrtle Potter, Chairman of the
Urovant Sciences Board. “Given the trajectory of Urovant, Jim’s
extensive commercial experience will certainly benefit Urovant and its
management team.”

Mr. Robinson has more than 27 years of commercial and operations
experience in the biopharmaceutical industry, specifically in the
urology, oncology, cardiovascular, infectious disease, hepatitis and CNS
markets. Since March 2018, he has held the position of President and
Chief Operating Officer at Alkermes, where he is responsible for the
global commercial, new product planning, corporate planning,
manufacturing, quality, human resource and business development
functions. Prior to Alkermes, Mr. Robinson spent over 13 years at
Astellas US – most recently as President, Americas Operations, from
April 2016 through February 2018, where his responsibilities included
all aspects of commercial, corporate development, human resources,
finance, corporate affairs, compliance, legal and international
operations for North and South America. Prior to his role as President
of Americas Operations, Mr. Robinson was President, Astellas Pharma US,
from April 2013 through March 2016, where he was responsible for leading
the US commercial organization. Prior to Astellas, Mr. Robinson spent 13
years at Schering-Plough Pharmaceuticals where his last role was Vice
President, Hepatitis Sales and Managed Care.

“I am pleased to join Urovant’s board and work with a company that is
passionate about developing and commercializing innovative products to
address the needs of urology patients who oftentimes suffer in silence,”
said Mr. Robinson. “I look forward to working with Keith and his
leadership team.”

Mr. Robinson serves on the Board of Directors for Neos Therapeutics. He
is a founding member and serves on the Board of Directors of MATTER and
is also on the Board of Directors for the Chicago Botanic Garden. He
received his Bachelor of Science degree from DePaul University.

About Urovant Sciences

Urovant Sciences is a clinical-stage biopharmaceutical company focused
on developing and commercializing innovative therapies for urologic
conditions. Urovant’s lead product candidate, vibegron, is an oral,
once-daily, small molecule beta-3 agonist being evaluated for the
treatment of OAB with symptoms of urge urinary incontinence, urgency,
and urinary frequency; for OAB in men with benign prostatic hyperplasia;
and for abdominal pain associated with irritable bowel syndrome. Urovant
has licensed global rights, excluding Japan and certain Asian
territories, for the development and commercialization of vibegron.
Urovant’s second product candidate, URO-902, is a novel gene therapy
being developed for patients with OAB who have failed oral
pharmacological therapy. Urovant intends to develop treatments for
additional urologic diseases. For more information, please visit www.urovant.com.


Investor inquiries: Investors@Urovant.com
inquiries: Media@Urovant.com

error: Content is protected !!